Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer

-- Infinity Advances Hedgehog Pathway Inhibitor Into Later Clinical Development --

-- New Preclinical Data in Several Cancer Indications Further Support Broad Therapeutic Potential of IPI-926 --

Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer. In addition, Infinity reported new preclinical data on IPI-926 during the 2010 American Association of Cancer Research (AACR) Annual Meeting demonstrating that IPI-926 delays tumor re-growth after regression of the tumors by chemotherapy and by targeted therapy, further supporting the potential for Hedgehog pathway inhibition by IPI-926 in a broad range of difficult to treat cancers.

"We are excited to evaluate IPI-926 in a clinical study that builds upon the encouraging preclinical data we have generated in which Hedgehog pathway inhibition may improve access of chemotherapeutics to tumors by altering the tumor microenvironment," said Vito Palombella, Ph.D., vice president of drug discovery, Infinity. "Pancreatic cancer is an aggressive disease with few meaningful therapeutic options. We believe the administration of IPI-926 in combination with chemotherapy may represent a new approach to improving outcomes in patients with this disease."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ultrasound technology breaks blood-brain barrier for glioblastoma treatment